## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.9% below STRENGTH zone (3.0-6.0%); PEG 2.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($533.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. London & Capital Asset Management Ltd Has $10.76 Million Stake in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251209T131736 | Somewhat-Bullish | Relevance: 100%
-  London & Capital Asset Management Ltd reduced its stake in Intuitive Surgical, Inc. by 56.2% in the second quarter, ending with holdings valued at $10.76 million. Other institutional investors like Norway Savings Bank, Trust Co. of Oklahoma, IronOak Wealth LLC, Amalgamated Bank, and Eastover Investment Advisors LLC adjusted their positions, with several increasing their holdings. Insider selling also occurred, with executives Charlton and Guthart selling shares totaling over $23 million, while analysts maintain a "Moderate Buy" consensus rating for the stock.

**2. Jump Financial LLC Purchases 8,815 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251207T114325 | Bullish | Relevance: 99%
-  Jump Financial LLC increased its stake in Intuitive Surgical, Inc. by 16.8%, acquiring an additional 8,815 shares, bringing their total holdings to 61,379 shares valued at approximately $33.35 million. This move is part of a broader trend of increased institutional investment in ISRG, with major entities like Norges Bank and Vanguard Group significantly expanding their positions. Intuitive Surgical, Inc. recently exceeded quarterly earnings estimates and maintains a "Moderate Buy" consensus rating from Wall Street analysts, with an average price target reflecting confidence in its continued growth.

**3. Natixis Has $65.35 Million Stake in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251208T130821 | Somewhat-Bullish | Relevance: 99%
-  Natixis significantly increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 30.7% during the second quarter, bringing its total holdings to 120,254 shares valued at $65.35 million. This move is part of broader institutional investor activity in ISRG stock, with several other hedge funds also adjusting their positions. Despite recent insider selling, analysts generally maintain a "Moderate Buy" rating for the company, with a consensus price target of $607.17.

**4. Vega Investment Solutions Sells 10,530 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251208T130837 | Neutral | Relevance: 99%
-  Vega Investment Solutions significantly reduced its stake in Intuitive Surgical, Inc. by selling 10,530 shares, bringing its total holdings to 7,265 shares valued at $3.95 million. Despite this, other institutional investors like Winslow Capital Management increased their positions, while company insiders sold a substantial amount of shares. Analysts maintain a "Moderate Buy" consensus for ISRG with a target price of $607.17, amidst strong Q3 earnings and a high P/E ratio.

**5. Winslow Capital Management LLC Grows Stock Position in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251208T132524 | Somewhat-Bullish | Relevance: 98%
-  Winslow Capital Management LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.2% in Q2, making it their 13th largest holding. Despite this institutional accumulation, company insiders, including CEO Gary S. Guthart and EVP Henry L. Charlton, sold significant portions of their shares, totaling approximately $60.8 million. Intuitive Surgical recently surpassed Q3 earnings and revenue expectations, and the stock currently holds a "Moderate Buy" consensus rating from analysts with a target price of $607.17.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($4.83M) |
| Sells | 10 ($1.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Premium valuation (P/E 57x, PEG 2.8x) vulnerable to multiple compression.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.79 signals overvaluation risk, limited margin of safety. Forward P/E 57.4x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Insider buying signal ($4.8M), management confidence. Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $200.1B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.79 |
| Forward P/E | 57.4 |
| Current P/E | 64.7 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -1.8% to -2.9% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-3.60), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.85% (CS: 26) | Weak |
| RSI_14 | 52.4 | Neutral |
| MACD Histogram | -3.60 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.072x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $558.13
- **Stop Loss:** $533.27 (4.5% risk)
- **Target:** $582.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $6,697.56
- **Portfolio %:** 6.70%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*